I型糖尿病,降糖药 z-bo 2020-11-02 299

　　According to a new study published in The Lancet, hypoglycemic drugs commonly used by patients with type 2 diabetes can protect the kidneys of patients with type 1 diabetes.

　　The hypoglycemic drugs commonly used by patients with type 2 diabetes can protect the kidneys of patients with type 1 diabetes. According to the results of a new study published in The Lancet.

　　Professor Johan Jendle of the University of Orebro said: “This may be huge and cause many people to change treatments. Kidney failure is a major problem that causes both patient suffering and high costs. However, further steps are needed. Research to confirm these findings."

　　Dapagliflozin has been shown to protect the kidneys of patients with type 2 diabetes, and researchers want to know whether it has the same effect on patients with type 1 diabetes. The new study included 251 patients with type 1 diabetes who had increased protein content in their urine. Participating patients were divided into three groups: one group received a placebo, another group received a low dose of dapagliflozin 5 mg, and the third group received a slightly higher dose of 10 mg. The researchers then compared the protein levels in the urine of the participants.

　　"We checked the function of the kidneys. High blood sugar and high blood pressure make the kidneys fragile and unable to cope. I usually rupture the coffee filter, grind it, and then enter the coffee. We don't want protein to pass into the urine." John · Zander explained.

　　In the lower dose group, the protein level in urine decreased by 13%, while in the higher dose group, the protein level in urine decreased by 31%.

　　Johan Jendle said: "In addition, the secondary impact is very small."

　　The serious side effect of the drug category to which dapagliflozin belongs is the increased risk of increased ketone bodies in the blood. Ketones are a sign of acute insulin deficiency and can lead to ketoacidosis. None of the patients in the placebo group had this condition. Among low-dose dapagliflozin patients, 1% had ketones in their blood, while 4% of patients receiving high-dose dapagliflozin.

　　In this study, 3% of the placebo group received low-dose or high-dose dapagliflozin, and 5% and 6% had common genital infections, respectively. Researchers also found an increase in urinary tract infections in patients taking the drug.

　　"These side effects are consistent with those previously reported in patients with type 2 diabetes. Even if the number is small, our goal is to use the lowest possible dose to avoid possible side effects. This is the first time we have shown that insulin Adjuvant therapy can reduce the incidence of renal complications." Johan Jendle said.

　　Since renal protection is not a pre-specified endpoint in the study, but is based on previously collected data, the next step is to conduct so-called prospective randomized clinical trials to confirm the results.